CNS vs NERV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and NERV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and NERV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. Its lead and defining program is roluperidone, an investigational drug aimed at treating the negative symptoms of schizophrenia, a hard-to-treat area with limited approved options. As a clinical-stage company, Minerva has no approved products and generates no product revenue; its financial statements are characterized by research and development spending and operating losses funded by cash raised from investors. That makes it fundamentally different from a profitable, revenue-generating pharmaceutical company, and its share price tends to move on clinical and regulatory news rather than on sales or earnings.

Full NERV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
• NERV drivers: Roluperidone Phase 3 confirmatory trial; FDA path after the Complete Response Letter.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For NERV, the overriding risk is binary clinical and regulatory outcome.

Pick CNS if you believe its drivers more; NERV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNS and NERV guides.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

NERV. These are qualitative descriptions, not precise financial figures. As a clinical-stage biotech, Minerva has no meaningful revenue or earnings, so conventional metrics like P/E do not apply and valuation is driven by the probability-weighted outcome of roluperidone. The most important numbers to verify in the latest filings are cash and marketable securities, quarterly cash burn, shares outstanding, and warrant terms, since these determine how far the company can fund itself toward the 2027 readout. Confirm all live figures directly before acting; this page is general information, not investment advice.

Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; NERV shows company type Clinical-stage biopharmaceutical company; no approved product and no product revenue, lead asset Roluperidone for negative symptoms of schizophrenia; essentially a single-asset story, regulatory status FDA issued a Complete Response Letter in 2024; a confirmatory Phase 3 trial is underway to address it, key catalyst Phase 3 topline efficacy data expected in the second half of 2027.

CNS and NERV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and NERV exposure against your real portfolio. It is not an investment adviser.